Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CMO Noah Rosenberg bought 4,200 shares of the company’s stock in a transaction on Monday, August 17th. The stock was purchased at an average cost of $4.91 per share, for a total transaction of $20,622.00. Following the completion of the transaction, the chief marketing officer owned 6,557 shares in the company, valued at approximately $32,194.87. The trade was a 178.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Verrica Pharmaceuticals Stock Down 4.3%

VRCA opened at $4.68 on Wednesday. Verrica Pharmaceuticals Inc. has a fifty-two week low of $3.28 and a fifty-two week high of $9.82. The business has a 50-day moving average of $5.65 and a 200-day moving average of $5.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.45 and a quick ratio of 1.33. The company has a market capitalization of $80.40 million, a PE ratio of -2.80 and a beta of 1.49.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, HC Wainwright started coverage on shares of Verrica Pharmaceuticals in a research note on Tuesday, May 26th. They issued a “buy” rating and a $12.00 price objective for the company. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Verrica Pharmaceuticals currently has an average rating of “Hold” and an average price target of $14.50.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VRCA. AQR Capital Management LLC raised its position in shares of Verrica Pharmaceuticals by 306.7% in the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock valued at $26,000 after purchasing an additional 44,275 shares during the period. Qube Research & Technologies Ltd bought a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter worth $28,000. Invesco Ltd. boosted its holdings in shares of Verrica Pharmaceuticals by 64.8% during the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock worth $33,000 after buying an additional 29,256 shares during the period. Bridgeway Capital Management LLC acquired a new position in Verrica Pharmaceuticals in the 3rd quarter valued at $52,000. Finally, Goldman Sachs Group Inc. raised its holdings in Verrica Pharmaceuticals by 23.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company’s stock worth $61,000 after acquiring an additional 26,308 shares during the period. Institutional investors and hedge funds own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.